Discontinued — last reported Q4 '25
CRH Acquisitions decreased by 82.9% to $126.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 78.5%, from $585.00M to $126.00M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows an upward trend with a 26.7% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $373.50M | $373.50M | $373.50M | $813.25M | $813.25M | $813.25M | $813.25M | $155.00M | $43.00M | $363.00M | $79.00M | $2.21B | $316.00M | $1.33B | $1.05B | $585.00M | $63.00M | $2.47B | $735.00M | $126.00M |
| QoQ Change | — | +0.0% | +0.0% | +117.7% | +0.0% | +0.0% | +0.0% | -80.9% | -72.3% | +744.2% | -78.2% | >999% | -85.7% | +321.2% | -21.3% | -44.1% | -89.2% | >999% | -70.3% | -82.9% |
| YoY Change | — | — | — | — | +117.7% | +117.7% | +117.7% | -80.9% | -94.7% | -55.4% | -90.3% | >999% | +634.9% | +266.7% | >999% | -73.5% | -80.1% | +85.8% | -29.8% | -78.5% |